Home > Healthcare > Pharmaceuticals > Finished Drug Form > Erythropoietin Drugs Market

Erythropoietin Drugs Market Size

  • Report ID: GMI10624
  • Published Date: Aug 2024
  • Report Format: PDF

A PHP Error was encountered

Severity: Warning

Message: getimagesize(rythropoietin Drugs Market Size</h2> <p>Erythropoietin Drugs Market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032. Erythropoietin drugs are medications designed to stimulate the production of red blood cells (RBCs) in the body. They mimic the action of erythropoietin, a naturally occurring hormone produced by the kidneys that regulates red blood cell production. These drugs are primarily used to treat conditions characterized by anemia, which is a deficiency of red blood cells.<br width=): failed to open stream: No such file or directory

Filename: v2_reports/body1.php

Line Number: 435

Backtrace:

File: /home/admin/web/gminsights.com/public_html/application/views/v2_reports/body1.php
Line: 435
Function: getimagesize

File: /home/admin/web/gminsights.com/public_html/application/views/v2_layouts/master_header_footer.php
Line: 1201
Function: view

File: /home/admin/web/gminsights.com/public_html/application/controllers/Reports.php
Line: 703
Function: view

File: /home/admin/web/gminsights.com/public_html/index.php
Line: 305
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: getimagesize(rythropoietin Drugs Market Size</h2> <p>Erythropoietin Drugs Market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032. Erythropoietin drugs are medications designed to stimulate the production of red blood cells (RBCs) in the body. They mimic the action of erythropoietin, a naturally occurring hormone produced by the kidneys that regulates red blood cell production. These drugs are primarily used to treat conditions characterized by anemia, which is a deficiency of red blood cells.<br width=): failed to open stream: No such file or directory

Filename: v2_reports/body1.php

Line Number: 435

Backtrace:

File: /home/admin/web/gminsights.com/public_html/application/views/v2_reports/body1.php
Line: 435
Function: getimagesize

File: /home/admin/web/gminsights.com/public_html/application/views/v2_layouts/master_header_footer.php
Line: 1201
Function: view

File: /home/admin/web/gminsights.com/public_html/application/controllers/Reports.php
Line: 703
Function: view

File: /home/admin/web/gminsights.com/public_html/index.php
Line: 305
Function: require_once

Erythropoietin Drugs Market Size

Erythropoietin Drugs Market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032. Erythropoietin drugs are medications designed to stimulate the production of red blood cells (RBCs) in the body. They mimic the action of erythropoietin, a naturally occurring hormone produced by the kidneys that regulates red blood cell production. These drugs are primarily used to treat conditions characterized by anemia, which is a deficiency of red blood cells.

 

Erythropoietin Drugs Market

The rising prevalence of cancer is a significant driving factor for the market. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide. Thus, this underscores the growing demand for erythropoietin drugs, as they are essential in managing anemia associated with cancer treatments, helping to improve patient outcomes and quality of life.
 

Furthermore, rising prevalence of chronic kidney disease (CKD), advancements in drug formulations, and rising geriatric population are the promoting factors advancing the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Erythropoietin drugs market size was valued at around USD 10.4 billion in 2023 and is estimated to grow at 4.5% CAGR from 2024 to 2032 owing to the rising prevalence of cancer.

The biosimilars segment in the market is forecast to reach USD 7 billion by 2032 as they are less expensive than their reference biologics, making healthcare more affordable.

The erythropoietin drugs market in the U.S. is projected to reach USD 5.8 billion by 2032 due to highly developed healthcare system with state-of-the-art medical facilities and advanced technology.

AstraZeneca PLC, Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., and Intas Pharmaceuticals Ltd. among others.

Erythropoietin Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 284
  • Countries covered: 23
  • Pages: 159
 Download Free Sample